MedTrace Logo

Enhanced Recovery After Surgery (ERAS) in Live Donor Kidney Transplant Recipients

NCT06997016 · Status: ENROLLING_BY_INVITATION · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-01-27

No results posted yet for this study

Summary

The goal of this interventional study is to learn if an Enhanced Recovery After Surgery (ERAS) protocol works to reduce the need for narcotic pain medications in live donor kidney transplant recipients. The main questions it aims to answer are:

Does the ERAS protocol lower the amount of opioid narcotic medication needed to manage post-surgery pain? Does the ERAS protocol help lower pain scores after surgery? Researchers will compare the ERAS protocol to previous patients where the ERAS protocol was not used to see if the ERAS protocol works to reduce post-surgery pain.

Participants will be asked to:

* Drink a pre-surgery carbohydrate drink two hours before your surgery.
* Take a pre-surgery dose of Tylenol by mouth.
* Take a pre-surgery dose of Gabapentin by mouth.
* The surgeon will administer a local numbing medication at the surgery site by injection during the surgery.
* Begin walking with assistance about 12 hours after your surgery.
* Allow the research staff to collect data about your kidney function. This data will be collected on your postoperative clinic visits, which generally occur about twice weekly for one month. This information will determine your kidney health, need for hospitalization, and side effects that may occur.

Conditions

  • Postoperative Pain

Interventions

DIETARY_SUPPLEMENT

pre-operative carbohydrate drink

50 g of carbohydrate drink 2 hours before surgery

DRUG

Acetaminophen

650mg acetaminophen 30 minutes prior to surgery

DRUG

Gabapentin

300 mg gabapentin 30 minutes prior to surgery

DRUG

Bupivacaine

intraoperative local anesthetic

OTHER

Ambulation

Assisted ambulation 12 hours after surgery

Sponsors & Collaborators

  • Baylor Research Institute

    lead OTHER

Principal Investigators

  • Richard Ruiz, MD · Baylor Scott & White All Saints Medical Center

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-05-05
Primary Completion
2026-06-30
Completion
2027-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06997016 on ClinicalTrials.gov